Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam is paying Tekmira $65 million to resolve an RNAi trade secrets suit; the new licensing pact reduces Alnylam’s future milestone and royalty payments on three compounds and allows the firm to manufacture its own drug candidates.